Antiretroviral Regime for Viral Eradication in Newborns
Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, controlled, open clinical trial. The trial will be
carried out in five provinces in China. Pregnant women with HIV infection and at high risk of
mother-to-child transmission of HIV will be identified. Their newborn babies who are at high
risk HIV infection will be recruited and randomized into intervention and control groups.
Children in intervention groups will receive ART and intensive HIV testing after birth.
Children in control group will receive routine prevention of mother-to-child transmission
services. All the included children will be followed up and their development and infection
status will be recorded and compared.
Phase:
Phase 4
Details
Lead Sponsor:
National Center for Women and Children's Health, China CDC
Collaborators:
Guangdong Provincial Maternal and Child Health Hospital Maternal and Child Health Hospital of Guangxi Province Maternal and Child Health Hospital of Sichuan Province Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region Maternal and Child Health Hospital of Yunan Province National Center for AIDS/STD Control and Prevention, China CDC